Table 3.
Meta-analysis of HHLA2 and clinicopathological features in cancer patients.
| Categories | Trials (Patients) | OR (95%CI) | I2(%) | Ph | Z | Pz |
| Age (young vs old) | 12 (1308) | 1.30 (1.03–1.63) | 0.0 | .525 | 2.24 | .025 |
| Gender (male vs female) | 9 (1004) | 1.21 (0.91–1.61) | 0.0 | .780 | 1.34 | .181 |
| Tumor size (small vs large) | 5 (465) | 1.28 (0.86–1.90) | 38.4 | .165 | 1.20 | .231 |
| Clinical stage (I–II vs. III–IV) | 13 (1391) | 1.68 (0.94–3.00)R | 77.7 | <.001 | 1.77 | .077 |
| Tumor depth (T0–T2 vs T3–T4) | 6 (510) | 1.67 (0.78–3.59)R | 58.6 | .034 | 1.32 | .188 |
| Lymph node metastasis (negative vs positive) | 9 (787) | 1.99 (1.41–2.81) | 26.5 | .208 | 3.93 | <.001 |
| Distant metastasis (negative vs positive) | 7 (611) | 1.52 (0.83–2.79) | 24.9 | .239 | 1.36 | .174 |
| vascular invasion (negative vs positive) | 7 (901) | 1.69 (1.18–2.42) | 0.0 | .548 | 2.86 | .004 |